Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial shows

Treatment with Endari (L-glutamine) leads to fewer pain crises and hospitalizations in patients with sickle cell disease, according to final results of a Phase 3 clinical trial.

These results were published in the study, “A Phase 3 Trial of l-Glutamine in Sickle Cell Disease,” in the New England Journal of Medicine.

Patients with sickle cell disease have increased levels of oxidative stress, which has been shown to contribute to the development of the disease. Oxidative stress occurs when the amount of oxygen-related toxic molecules exceeds the natural levels of counteracting antioxidants, leading to cellular damage.